Trivitron Digital AI融合了Trivitron Healthcare和ResoHealth的优势，提供创新解决方案，改变医院在患者 照护、数据管理与医患互动方面的工作模式，同时推动医疗系统的互操作性提升与运营效率优化。 格隆汇1月9日丨北大资源(00618.HK)宣布，ResoHealth(集团位于迪拜的健康业务板块)已与Trivitron Healthcare合作，共同推出了Trivitron Digital AI，这是一项突破性的数字健康计画，旨在革新印度二、 三线城市的医疗服务模式。这一战略合作将着力满足印度对先进数字基础设施的迫切需求。 Trivitron Digital AI旨在通过为医院提供集成化云端解决方案来缩小数字鸿沟，从而提升运营效率，实现 以患者为中心的AI智能诊疗。 ...

扬子晚报网1月7日讯(通讯员仇杰记者薛玲)扬子晚报记者从南京市鼓楼区华侨路街道获悉，位于汉中路6号的国药大厦更新改造项目，现已正式进入实施 阶段。未来这里将打造集研发、展示、运营于一体的现代化医药健康产业空间，为鼓楼区"环五台山大健康产业带"注入新动能。 国药大厦区位图 坐落于新街口商圈西北象限华侨路街道的国药大厦，处于鼓楼区重点规划的"环五台山大健康产业带"核心区域，这座始建于上世纪90年代的楼宇将在"城 市更新+产业焕新"的双轮驱动下，转型为聚焦"新医药与生命健康"的专项产业园区。这里也将成为新街口商圈首个"小而精"的大健康领域专项园区，重点 集聚新医药上下游企业及数字健康产业，形成"总部办公+产学研融合+产业孵化+创新服务+商务配套"的全链条生态，打造高品质"城市硅巷"。 视频｜薛玲 校对陶善工 国药大厦更新效果图 鼓楼区集聚了南京大学、南京医科大学、南京中医药大学等7所涉医院校、53个相关专业，拥有生命健康领域基础研究和创新药研发的宝贵智力资源。 与此同时，鼓楼区还聚合了江苏省人民医院、南京鼓楼医院等12家三级以上医院，具有得天独厚的健康产业发展生态。因此，鼓楼区将健康经济作为科创 先导产业的重要赛道 ...

2025年底，网经社启动2025《数字经济系列年终盘点&报告&百强榜》招商计划，本次计划全面覆盖数字零售、数字生活、移动出行、产业电商、跨境电 商、数字教育、数字健康、物流科技等主流赛道，现面向各领域企业开放优质内容资源合作，名额有限，预报从速。 1.年终盘点系列 岁末年初，网经社第17次例行启动电商与互联网【年终盘点】系列计划。这不仅仅是对过去一年大小事件的简单罗列，更是一次基于专业洞察的年度复盘与 趋势预判。 2025年生鲜电商大事件 2025年数字零售大事件 2025年内容电商大事件 2025年二手电商大事件 2025年物流科技大事件 2025年Al电商大事件 2025年阿里零售电商大事件 2025年拼多多大事件 2025年京东大事件 2025年直播电商大封禁处罚事件 2025年直播电商大偷税漏税事件 2025年零售电商政策 2025年"仅退款"大事记 2025年大Al "仅退款"奇葩案例 2025年淘系店铺闭店 跨境电商 2025年跨境电商大事件 2025年跨境电商物流大事件 2025年跨境电商卖家大事件 2025年出口跨境电商平台大事件 2025年中国跨境电商行业大政策 2025年Al跨境电商大事件 ...

以下文章来源于AI医疗观察 ，作者关注AI医疗的 AI医疗观察 . 响应《关于深入实施"人工智能+"行动的意见》，推动AI在医疗领域的应用，本账号发布权威资讯 *转载请联系后台，原创不易 把它和传统综合健康管理应用对比，会更清楚差异点。传统应用的干预是内容化的，例如给出饮食与运动建议，然后把执行交给用户。 WELT 这类产品把干预做成流程化的，持续监测腰围与行为模式，自动触发提醒与反馈，把健康行为拆成每天都会发生的小动作，系统承担了更大比例 的执行责任，而不是把责任留在用户端。 从建议到执行：综合健康管理正在把决策负担从人转移到系统 综合健康管理在 CES Digital Health 里是最拥挤的赛道之一。大量公司都在讲 AI、个性化、全维度健康，但真正的分化点并不在谁能覆盖更多 模块，而在产品是否对健康结果承担了更大的执行责任。这里的执行责任不是口号，而是产品结构上把原本由人完成的事情系统化，例如自动触 发、自动校正、自动把训练与干预排进日程，并且把反馈闭环绑定在硬件与家庭场景里，让健康行为不再依赖意志力与手动记录。 基于对 CES 官网展商公司介绍及产品分类 的逐条分析，我们将 92 家公司归入综合健康 ...

转自：新华财经 聚焦运营落地。近年来通过科技赋能不断提升公司全周期健康管理的服务能力。凭借"7+N+1"的AI医疗 产品体系创新，切实有效地大幅优化了医生服务效率和用户体验。据了解，平安好医生现已实现AI辅 助咨询问诊准确率超98%，复杂疾病的多学科会诊MDT治疗方案准确率近90%，稳稳处于行业领先地 位。秉持责任初心，公司不忘将普惠民生理念融入各项业务发展链条，包括坚持多年开展"国民健康素 养提升"系列社会公益、全国推行"高质量职场健康管理"等，实现了商业与社会价值双向提升，为品牌 长效发展注入不竭动力。 乘"健康中国2030"与"人工智能+"行动的政策机遇与东风，当下大医疗健康产业正从"以治病为中心"转 向"以健康为中心"，从"粗放式发展"走向"精细化、科技化、规范化"管理。平安好医生表示，未来将不 变"省心省时又省钱"的品牌主张，以匠心打磨产品，以服务铸就口碑，让更多优质健康保障惠及千家万 户。（湛玮琦） 编辑：姜楠 近日，经中国广告协会、国家广告研究院及方圆标识认证集团联合评定，授予平安健康互联网股份有限 公司（以下简称：平安好医生）品牌发展力评级--AAAA级认证。品牌发展力评价是基于《品牌发展 力 ...

2025年6月，杭州微脉技术有限公司（下称"微脉"）向港交所递交主板上市申请。作为国内较早提出"全病程管理"概念的企业，微脉曾因嵌入公立医院体 系、以AI驱动患者管理服务而受到市场关注。然而，招股书披露的财务数据与最新监管动态揭示出多重挑战：营收增长几近停滞、三年累计亏损超全年收 入、研发投入持续萎缩。根据港交所披露最新信息其首次港股IPO尝试目前审核状态为失效。 营收停滞，三年累计亏损超全年收入 表面的营收增长难掩增长乏力的窘境。根据微脉2025年7月3日提交的上市申请文件，2022年至2024年公司营收分别为5.12亿元、6.28亿元和6.53亿元，2023 年同比增长22.7%，但2024年增速骤降至3.98%，几近停滞。 盈利能力更是核心痛点。同期，微脉净亏损分别为4.14亿元、1.50亿元和1.93亿元，三年累计亏损达7.57亿元，相当于2024年全年营收的1.16倍。尽管公司强 调"经调整净亏损"已收窄至3020万元，但这一数据剔除了股权激励等非现金项目，实际经营性现金流仍持续为负——2022年至2024年经营活动所得现金净额 分别为-2.43亿元、-0.83亿元和-0.39亿元，意味着靠现有业务 ...

Group 1 - The core viewpoint of the article highlights that Brainstorm Cell Therapeutics (06681) has seen a significant stock price increase, rising over 8% during trading and currently up 5.87% to HKD 6.67, with a trading volume of HKD 110 million [1] - The company announced a strategic cooperation agreement with Singapore's Laheyspring Health Management Group to promote product marketing and market expansion in Singapore, aiming to advance the digital health industry [1] - In terms of product promotion, the company will localize and implement its cognitive impairment digital therapy products in Singapore, providing system support and personnel training, while Laheyspring will leverage its offline stores and member resources to recommend the company's products to target users [1] Group 2 - For market expansion collaboration, both parties will integrate resources such as products, channels, brands, and technology to jointly explore the Singapore market, focusing on introducing the company's products into leading private and public hospitals in Singapore to enhance their application and popularity within the local healthcare system [1]

Core Viewpoint - The company, Brainstorm Cell Therapeutics (脑动极光-B), has seen its stock price increase by over 8% during trading, currently up by 5.87% at HKD 6.67, with a trading volume of HKD 110 million, following the announcement of a strategic partnership with Singapore's Lehe Health Management Group [1] Group 1: Strategic Partnership - The company has entered into a strategic cooperation agreement with Lehe Health Management Group to promote and expand its products in the Singapore market [1] - The collaboration will focus on the localization, system implementation, and personnel training support for cognitive impairment digital therapy products in Singapore [1] - Lehe Health Management Group will utilize its offline stores and member resources to target users for the company's products, providing comprehensive services including product introduction, trial guidance, purchase conversion, and after-sales support [1] Group 2: Market Expansion - Both companies will integrate their resources in products, channels, branding, and technology to jointly explore the Singapore market [1] - The partnership aims to facilitate the entry of the company's products into leading private and public hospitals in Singapore, enhancing the application and popularity of its products within the local healthcare system [1]

Core Viewpoint - The company Brainstorm Aurora-B (06681) has entered a strategic cooperation agreement with Singapore's Lehasiba Health Management Group to promote and expand its digital health products in the Singapore market [1] Group 1: Strategic Cooperation - The agreement focuses on product promotion and market expansion collaboration in Singapore [1] - Brainstorm Aurora will localize its cognitive impairment digital therapy products, support system implementation, and provide personnel training [1] - Lehasiba will utilize its offline stores and member resources to recommend the company's products to target users and manage the entire service process, including product introduction, trial guidance, purchase conversion, and after-sales support [1] Group 2: Market Expansion - Both companies will integrate resources such as products, channels, brands, and technology to jointly explore the Singapore market [1] - The collaboration aims to promote the company's products into leading private hospitals and public hospital systems in Singapore, enhancing the application and popularity of the products within the local healthcare system [1]

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation Details - The cooperation includes product promotion, where the company will localize its cognitive disorder digital therapy products for Singapore, while Natural Health Solutions will leverage its offline stores and member resources for targeted recommendations and full-service support [2]. - Market expansion efforts will involve integrating resources such as products, channels, brands, and technology to penetrate Singapore's healthcare system, focusing on private and public hospitals [2]. Group 2: Long-term Development Opportunities - This partnership is expected to enhance the company's international presence and expand into Southeast Asia, building on previous experiences in Hong Kong and Macau [3]. - The collaboration aims to strengthen the company's brand authority in digital healthcare and expedite product integration into local medical institutions, thereby broadening its market reach [3].